LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 111 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3 | -40.0% | 3,319 | +0.8% | 0.00% | – |
| Q1 2024 | $5 | +66.7% | 3,292 | +4.2% | 0.00% | – |
| Q4 2023 | $3 | -25.0% | 3,160 | -11.1% | 0.00% | – |
| Q3 2023 | $4 | -95.8% | 3,555 | -94.7% | 0.00% | – |
| Q2 2023 | $95 | -90.5% | 67,600 | +7353.1% | 0.00% | – |
| Q2 2022 | $1,000 | -99.1% | 907 | -98.7% | 0.00% | – |
| Q1 2022 | $106,000 | -37.3% | 69,129 | +0.3% | 0.00% | – |
| Q4 2021 | $169,000 | -2.9% | 68,922 | -0.3% | 0.00% | – |
| Q3 2021 | $174,000 | -41.2% | 69,150 | -33.4% | 0.00% | – |
| Q2 2021 | $296,000 | +410.3% | 103,900 | +49.5% | 0.00% | – |
| Q1 2020 | $58,000 | -6.5% | 69,500 | 0.0% | 0.00% | – |
| Q4 2019 | $62,000 | -8.8% | 69,500 | 0.0% | 0.00% | – |
| Q3 2019 | $68,000 | – | 69,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |